Immunohistochemical expression of P53 and oncogenes in ulcerative colitis-associated colorectal carcinoma

World Journal of Surgery

Volumn 26, Issue 3, 2002, Pages 390-396

  Brüwer, Matthias ^a   Schmid, Kurt W ^b   Senninger, Norbert ^a   Schürmann, Guido ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; COLON CARCINOGENESIS; COLON RESECTION; COLORECTAL CARCINOMA; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; ONCOGENE; PROTEIN EXPRESSION; RISK FACTOR; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS; CARCINOMA; COLORECTAL TUMOR; FEMALE; GENE EXPRESSION; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; PROTO ONCOGENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENES, P53; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENES; RISK FACTORS;

EID: 0036511424     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-001-0237-7     Document Type: Article

References (49)

1. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71-74
2. Lennard-Jones JE, Melville DM, Morson B, et al. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990;31:800-806
3. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer: a population-based study. N. Engl. J. Med. 1990;323:1228-1233
4. Greenstein AJ, Sachar DB, Smith H, et al. Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 1979;77:290-294
5. Sugita A, Sachar DB, Bodian C, et al. Colorectal cancer in ulcerative colitis: influence of anatomic extent and age of onset on colitis-cancer interval. Gut 1991;32:167-169
6. Herfarth C, Heuschen G, Heuschen UA. Die maligne Entartung der Colitis ulcerosa und ihre chirurgischen Implikationen. Chirurg 1998;69:1020-1027
7. Melville DM, Jass JR, Morson BC, et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum. Pathol. 1989;20:1008-1014
8. Baba S. Recent advances in molecular genetics of colorectal cancer. World J. Surg. 1997;21:678-687
9. Greenwald BD, Harpaz N, Yin J, et al. Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res. 1992;52:741-745
10. Lashner BA, Shapiro BA, Husain A, et al. Evaluation of the usefulness of testing p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am. J. Gastroenterol. 1999;94:456-462
11. Sato A, MacHinami R. P53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma. Pathol. Int. 1999;49:858-868
12. Benhattar J, Saraga E. Molecular genetics of dysplasia in ulcerative colitis. Eur. J. Cancer 1995;31:1171-1173
13. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767
14. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994;107:369-378
15. Burmer GC, Rabinovitch PS, Haggitt RC, et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 1992;103:1602-1610
16. Fogt F, Zhuang Z, Poremba C, et al. Comparison of p53 immunoexpression with allelic loss of p53 in ulcerative colitis-associated dysplasia and carcinoma. Oncol. Rep. 1998;5:477-480
17. Yin J, Harpaz N, Tong Y, et al. P53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993;104:1633-1639
18. Baker SJ, Preisinger AC, Jessup JM, et al. P53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717-7722
19. Shaw P, Bovey R, Tardy S, et al. Induction of apoptosis by wild type p53 in a human colon tumor derived cell line. Proc. Natl. Acad. Sci. U.S.A. 1992;89:4495-4499
20. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Gene Dev. 1995;9:1149-1163
21. Miyashita T, Krajewski S, Krajewski M, et al. Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-1805
22. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245
23. Bankfalvi A, Navabi H, Bier B, et al. Wet autoclave pretreatment for antigen retrieval in diagnostic immunochemistry. J. Pathol. 1994;174:223-228
24. Baas IO, Mulder J, Offerhaus GJ, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol. 1994;172:5-12
25. Rodrigues NR, Rowan A, Smith MEF, et al. P53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 1990;87:7555-7559
26. Calzolari A, Chiarelli I, Bianchi S, et al. Immunohistochemical vs molecular biology methods: complementary techniques for effective screening of p53 alterations in head and neck cancer. Am. J. Clin. Pathol. 1997;107:7-11
27. Harpaz N, Peck AL, Yin J, et al. P53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum. Pathol. 1994;25:1069-1074
28. Arai N, Mitorni H, Ohtani Y, et al. Enhanced epithelial cell turnover associated with p53 accumulation and high p21waf1/cip1 expression in ulcerative colitis. Mod. Pathol. 1999;12:604-611
29. Crary GS, Albrecht H. Expression of cyclin-dependent kinase inhibitor p21 in human liver. Hepatology 1998;28:738-743
30. Ihling C, Menzel G, Wellens E, et al. Topographical association between the cyclin-dependent kinases inhibitor p21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue. Arterioscler. Thromb. Vasc. Biol. 1997;17:2218-2224
31. Kuwano K, Kunitake R, Kawasaki M, et al. P21 waf1/cip1/sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1996;154:477-483
32. Doglioni C, Pelosio P, Laurino L, et al. P21/waf1/cip1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J. Pathol. 1996;179:248-253
33. Polyak K, Hamilton SR, Vogelstein B, et al. Early alteration of cell cycle regulated gene expression in colorectal neoplasia. Am. J. Pathol. 1996;149:381-387
34. Cartwright CA, Coad CA, Egbert BM. C-scr tyrosine kinase activity: a marker of dysplasia in ulcerative colitis. J. Clin. Invest. 1994;93:509-515
35. Noffsinger AE, Miller MA, Cusi MV, et al. The pattern of cell proliferation in neoplastic and nonneoplastic lesions of ulcerative colitis. Cancer 1996;78:2307-2312
36. Sjbquist U, Öst A, Löfberg R. Increased expression of proliferative Ki-67 nuclear antigen is correlated with dysplastic colorectal epithelium in ulcerative colitis. Int. J. Colorectal Dis. 1999;14:107-113
37. Itzkowitz SH, Marshall A, Kornbluth A, et al. Sialosyl-Tn antigen: initial report of a new marker of malignant progression in long-standing ulcerative colitis. Gastroenterology 1995;109:490-497
38. El-Deiry WS, Tokino T, Velculescu VE, et al. Waf-1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825
39. Tsuda T, Mochizuki M, Wakasa H. Detection of c-ras gene mutation and expression of p21 protein in dysplasias and carcinomas complicating ulcerative colitis. J. Gastroenterol. 1995;30:30-32
40. Moskaluk CA, Heitmiller R, Zahurrak M, et al. p53 and p21 (WAF1/CTP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum. Pathol. 1996;27:1211-1220
41. Sinicrope FA, Roddey G, Lemoine M, et al. Loss of p21 waf1/cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers. Clin. Cancer Res. 1998;4:1251-1261
42. Barak Y, Oren M. Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J. 1992;11:2115-2121
43. Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding p53 associated protein in human sarcomas. Nature 1992;358:80-83
44. Kanavaros P, Stefanaki K, Valassiadou J, et al. Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal carcinomas. Med. Oncol. 1999;16:23-30
45. Ilyas M, Tomlinson IP, Hanby A, et al. Bcl-2 expression in colorectal tumors: evidence of different pathways in sporadic and ulcerative colitis-associated carcinomas. Am. J. Pathol. 1996;149:1719-1726
46. Sinicrope FA, Ruan S, Clearly KR, et al. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995;55:237
47. Scott N, Martin I, Jack AS, et al. Genes mediating programmed cell death: an immunohistochemical study of bcl-2, c-myc and p53 expression in colorectal neoplasia. J. Clin. Pathol. 1996;49:M151
48. Öfner D, Maier H, Riedmann B, et al. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. J. Clin. Pathol. 1995;48:M12
49. Lang SM, Stratakis DF, Heinzlmann M, et al. Molecular screening of patients with longstanding ulcerative colitis: detection of p53 and Ki-ras mutations by single strand conformation polymorphism analysis and differential hybridisation in colonic lavage fluid. Gut 1999;44:822-825